Home

John A Stalfort III

CIK 1709418 · last filed 2026-06-05

John A Stalfort III is a corporate insider who has filed 19 SEC Form 4 insider transactions across 4 companies since 2018. The most recent filing, for ABOS, was dated Jun 5, 2026. Across all open-market trades the lifetime net is +$2.3M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $11.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$11.39M

Companies

4

Total Filings

19

Lifetime Open-Market Net

$2.25M

Filer Profile

Reported Address
C/O ACUMEN PHARMACEUTICALS, INC.
427 PARK STREET
CHARLOTTESVILLE, VA 22902
Formerly Known As
Stalfort Sean (2017–2020)
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ABOS Director 352,219 $2.23 $787.2K $560.0K 7 2026-06-05
TSHA Director 2,060,849 $4.74 $9.76M $700.0K 5 2026-06-02
VRCA Director 187,380 $4.49 $841.3K $796.8K 5 2024-11-26
Dova Pharmaceuticals Inc. (DOVA) Delisted Director 0 — — $194.1K 2 2019-11-12

Recent Filings

19 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-05 ABOS Grant (A) +35,500 $0 EDGAR
2026-06-02 TSHA Grant (A) +21,335 $0 EDGAR
2025-06-05 ABOS Grant (A) +12,800 $0 EDGAR
2025-06-04 TSHA Grant (A) +56,623 $0 EDGAR
2024-11-26 VRCA Mixed +1,173,595 $0 EDGAR
2024-06-10 ABOS Grant (A) — $0 EDGAR
2024-05-31 TSHA Grant (A) +49,220 $0 EDGAR
2023-08-16 TSHA Mixed +827,778 $700.0K EDGAR
2023-06-26 TSHA Grant (A) — $0 EDGAR
2023-06-07 ABOS Grant (A) — $0 EDGAR
Showing 1–10 of 19
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.